This protocol lets us investigate drug-eluting stents in a small animal model of laryngotracheal stenosis letting us leverage genetically modified animals in a cost effective manner. Transoral placement of the drug-eluting airway stent spares the
Bu içeriğe erişmek için giriş yapın veya ücretsiz denemenizi başlatın
Laryngotracheal stenosis results from pathologic scar deposition that critically narrows the tracheal airway and lacks effective medical therapies. Using a PLLA-PCL (70% poly-L-lactide and 30% polycaprolactone) stent as a local drug delivery system, potential therapies aimed at decreasing scar proliferation in the trachea can be studied.